<DOC>
	<DOCNO>NCT02222948</DOCNO>
	<brief_summary>Primary Objectives : - To assess efficacy vatelizumab compare placebo measure reduction new contrast-enhancing lesion ( CELs ) relapse remit multiple sclerosis ( RRMS ) patient . - To evaluate multiple dos vatelizumab dose-response . Secondary Objectives : - To evaluate safety tolerability vatelizumab compare placebo . - To evaluate pharmacokinetics ( PK ) vatelizumab .</brief_summary>
	<brief_title>Efficacy Safety Vatelizumab Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>The duration study per patient 108 week , include screen period 4 week , treatment period 12 week post-treatment safety follow-up period 92 week . Patients complete 12-week treatment period may enter optional long-term extension study subject receive vatelizumab .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion criterion : Diagnosis relapsingremitting multiple sclerosis ( RRMS ) . At least 1 documented relapse past 12 month . At least 1 contrastenhancing lesion ( CEL ) magnetic resonance imaging ( MRI ) past 12 month and/or screen . At least 3 T2 lesion screen MRI . Exclusion criterion : Diagnosis primary progressive secondary progressive MS . Expanded disability status scale ( EDSS ) score &gt; 5.5 . Relapse within 30 day prior enrollment . Prior immunosuppressive treatment within protocolspecified time period . Prior treatment natalizumab ( TysabriÂ® ) . History bleeding/platelet disorder , malignancy , certain infection define protocol , past current medical condition would adversely affect patient 's participation study . Pregnancy breastfeeding . Other protocoldefined inclusion/exclusion criterion may apply . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>